ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 125068" data-attributes="member: 13851"><p><strong>The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent. A personal perspective </strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">The first phase:</span> <em>the vasodilator action of on demand administration of PDE5 inhibitors for erectile dysfunction (ED) </em></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong><span style="color: rgb(184, 49, 47)">The second phase:</span> <em>the antifibrotic/smooth muscle protective action of continuous long term administration (CLTA) of PDE5 inhibitors for corporal Veno-occlusive dysfunction (CVOD) and Peyronie’s disease (PD) </em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em></em></strong></p><p><strong><em>*In summary, </em></strong><em><strong>extensive evidence supports CLTA of PDE5i to halt or reverse fibrosis of the penile corpora cavernosa and tunica albuginea. Such treatment is expected to result in permanently improved erectile function for many (although not all) ED patients, and to finally offer a non-surgical option or as a co-adjuvant for the treatment of PD. <u>Human studies have supported some of these preclinical findings and their interpretation, but their discussion is beyond the scope of this paper, although some reviews from other authors have stated the relevance of a primarily anti-fibrotic PDE5i strategy for the treatment of PD, coupled with its smooth muscle protection action for the treatment of CVOD, and lower urogenital tract symptoms (LUTS), mainly in the context of daily PDE5i</u> [22–28]. We look forward to seeing what new advances of PDE5i preclinical and clinical research will bring for their use as an anti-fibrotic and smooth muscle protective therapeutic approach, often coupled to stem cell treatment, not just for these conditions, but in other chronic serious fibrotic processes in various urological and non-urological conditions [17, 29–33].</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 125068, member: 13851"] [B]The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent. A personal perspective [COLOR=rgb(184, 49, 47)]The first phase:[/COLOR] [I]the vasodilator action of on demand administration of PDE5 inhibitors for erectile dysfunction (ED) [/I] [COLOR=rgb(184, 49, 47)]The second phase:[/COLOR] [I]the antifibrotic/smooth muscle protective action of continuous long term administration (CLTA) of PDE5 inhibitors for corporal Veno-occlusive dysfunction (CVOD) and Peyronie’s disease (PD) *In summary, [/I][/B][I][B]extensive evidence supports CLTA of PDE5i to halt or reverse fibrosis of the penile corpora cavernosa and tunica albuginea. Such treatment is expected to result in permanently improved erectile function for many (although not all) ED patients, and to finally offer a non-surgical option or as a co-adjuvant for the treatment of PD. [U]Human studies have supported some of these preclinical findings and their interpretation, but their discussion is beyond the scope of this paper, although some reviews from other authors have stated the relevance of a primarily anti-fibrotic PDE5i strategy for the treatment of PD, coupled with its smooth muscle protection action for the treatment of CVOD, and lower urogenital tract symptoms (LUTS), mainly in the context of daily PDE5i[/U] [22–28]. We look forward to seeing what new advances of PDE5i preclinical and clinical research will bring for their use as an anti-fibrotic and smooth muscle protective therapeutic approach, often coupled to stem cell treatment, not just for these conditions, but in other chronic serious fibrotic processes in various urological and non-urological conditions [17, 29–33].[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top